3 Key Takeaways
Plain English Summary- 01Core Finding
To date, little is known about the pattern and evolution of cognitive decline in PD GBA1 .
- 02Study Evidence
Tested in a observational cohort study at the real-world cohort stage.
- 03Practical Meaning
Observational cohort findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.
What This Means for You
PD GBA1 exhibits accelerated domain-generalized and more severe cognitive decline compared to PD GBA1_wildtype . ANN NEUROL 2026.
Published in Annals of neurology, these peer-reviewed neurology findings provide quantitative clinical evidence to inform risk stratification, therapeutic decision-making, and follow-up validation.
The Discovery
People with Parkinson's disease (PD) who carry a pathogenic GBA1 variant (PD GBA1 ) are at higher risk of cognitive impairment than those without the variant (PD GBA1_wildtype ). To date, little is known about the pattern and evolution of cognitive decline in PD GBA1 . This multicenter study characterized the cognitive profile of PD GBA , focusing on the longitudinal trajectories and the group-specific onset times among cognitive functions, as well as their clinical relevance. In this exploratory longitudinal multicohort-study (Parkinson's Precision Medicine Initiative [PPMI], Amyloid-Beta in cerebrospinal spinal fluid as a risk factor for cognitive dysfunction in Parkinson's Disease [ABC-PD], and National Centre for Excellence in Research on Parkinson's disease [NCER-PD]), comprehensive neuropsychological assessments were standardized across 546 healthy controls (follow-up years = 2.9 ± 4.3), 903 PD GBA1_wildtype (follow-up years = 4.4 ± 4.2), and 211 PD GBA1 (follow-up years = 4.8 ± 3.4). We evaluated performance across age and disease duration using generalized linear mixed effects models (GLMMs) within each cognitive domain. An exploratory latent trajectory analysis was computed to identify potential cognitive subgroups. Time-to-first-event models, assessing risks of clinically relevant performance impairment (test score z ≤ -1.5, Montreal Cognitive Assessment [MoCA] < 26), and an expanding time-window approach identified the course of cognitive impairment. PD GBA1 performed worse in executive function, attention, visuocognitive skills, and memory than PD GBA1_wildtype at baseline and exhibited a more rapid and widespread decline across these domains. The risk of developing clinically relevant cognitive impairment during the disease course was increased in PD GBA1 . Processing speed and visuoperceptual showed the earliest performance impairments in PD GBA1 , preceding PD GBA1_wildtype by 1.2 and 2.5 disease years, respectively. Within the PD GBA1 group, we identified a subgroup with rapidly declining cognition, who were more likely to be male patients, report depressive symptoms, and carry a severe GBA1 mutation.
How It Works, Simply
This neurology research focuses on amyloid. Researchers evaluated it using an observational cohort study at the real-world cohort stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
To date, little is known about the pattern and evolution of cognitive decline in PD GBA1 .
- 02Study Evidence
Tested in a observational cohort study at the real-world cohort stage.
- 03Practical Meaning
Observational cohort findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.
Biological Mechanism & Study Design
Study Design & Cohort
Observational cohort study
Observational cohort study · Real-World Cohort
Biological Pathway & Modality
Amyloid
Intervention: Understanding the Pattern of Cognitive Decline in GBA1-Related Parkinson's Disease
Experimental Findings & Endpoints
People with Parkinson's disease (PD) who carry a pathogenic GBA1 variant (PD GBA1 ) are at higher risk of cognitive impairment than those without the variant (PD GBA1_wildtype ).
To date, little is known about the pattern and evolution of cognitive decline in PD GBA1 . This multicenter study characterized the cognitive profile of PD GBA , focusing on the longitudinal trajectories and the group-specific onset times among cognitive functions, as well as their clinical relevance.
In this exploratory longitudinal multicohort-study (Parkinson's Precision Medicine Initiative [PPMI], Amyloid-Beta in cerebrospinal spinal fluid as a risk factor for cognitive dysfunction in Parkinson's Disease [ABC-PD], and National Centre for Excellence in Research on Parkinson's disease [NCER-PD]), comprehensive neuropsychological assessments were standardized across 546 healthy controls (follow-up years = 2.9 ± 4.3), 903 PD GBA1_wildtype (follow-up years = 4.4 ± 4.2), and 211 PD GBA1 (follow-up years = 4.8 ± 3.4). We evaluated performance across age and disease duration using generalized linear mixed effects models (GLMMs) within each cognitive domain.
An exploratory latent trajectory analysis was computed to identify potential cognitive subgroups. Time-to-first-event models, assessing risks of clinically relevant performance impairment (test score z ≤ -1.5, Montreal Cognitive Assessment [MoCA] < 26), and an expanding time-window approach identified the course of cognitive impairment.
PD GBA1 performed worse in executive function, attention, visuocognitive skills, and memory than PD GBA1_wildtype at baseline and exhibited a more rapid and widespread decline across these domains. The risk of developing clinically relevant cognitive impairment during the disease course was increased in PD GBA1 .
Processing speed and visuoperceptual showed the earliest performance impairments in PD GBA1 , preceding PD GBA1_wildtype by 1.2 and 2.5 disease years, respectively. Within the PD GBA1 group, we identified a subgroup with rapidly declining cognition, who were more likely to be male patients, report depressive symptoms, and carry a severe GBA1 mutation.
Clinical Translation & Practice Context
PD GBA1 exhibits accelerated domain-generalized and more severe cognitive decline compared to PD GBA1_wildtype .
ANN NEUROL 2026.
Published in Annals of neurology, these peer-reviewed neurology findings provide quantitative clinical evidence to inform risk stratification, therapeutic decision-making, and follow-up validation.
The Bottom Line · Clinical Pearl
“PD GBA1 exhibits accelerated domain-generalized and more severe cognitive decline compared to PD GBA1_wildtype .”
Published in Annals of Neurology · Current Stage: Real-World Cohort
